RCEL Stock Forecast & Price Target

AVITA Medical is benefiting from RECELL’s differentiated burn-care value proposition, which enables spray-on skin from a small sample within 30 minutes and reduces graft reliance, supporting adoption in most of the 140 U.S. burn centers. Revenue momentum is strong, with 3Q26 sales of about $26.1M rising 53.1% year over year and case volumes up roughly 20%+ sequentially to about 3,196, while FY26 guidance was raised to $92M-$94M and cash flow breakeven remains targeted for 4Q26. The outlook is further strengthened by clearer reimbursement after all seven MACs published payment rates, new CPT coding expected in 2027, and expanding adjacent products like Cohealyx and PermeaDerm that broaden the growth base and improve leverage.

AVITA Medical is a largely single-product company, so its outlook depends heavily on RECELL, and that concentration leaves the business exposed if adoption or execution weakens. The company raised FY guidance by about $5M at the midpoint after beating 2Q26 consensus by only about $1.4M, but that bigger increase risks scrutiny because it follows a period of weak forecasting accuracy through much of FY25. The guide also assumes sequential acceleration to roughly $22.2M in 3Q and $23.6M in 4Q, so any stumble could revive credibility concerns and underscore the fragility of its growth thesis.